Clinical implication of human leukocyte antigen (HLA)-F expression in breast cancer

Pathology International

Volumn 65, Issue 11, 2015, Pages 569-574

  Harada, Aya ^a   Ishigami, Sumiya ^a   Kijima, Yuko ^a   Nakajo, Akihiro ^a   Arigami, Takaaki ^a   Kurahara, Hiroshi ^a   Kita, Yoshiaki ^a   Yoshinaka, Heiji ^a   Natsugoe, Shoji ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Breast cancer; Clinical stage; HLA F; Tumor infiltrating cells

Indexed keywords

BIOLOGICAL MARKER; HLA F ANTIGEN; HLA ANTIGEN CLASS 1; HLA-F ANTIGENS; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CELL INFILTRATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE INTERVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MASTECTOMY; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; STROMA CELL; SURVIVAL RATE; TUMOR VOLUME; BREAST NEOPLASMS; CYTOLOGY; IMMUNOLOGY; LEUKOCYTE; METABOLISM; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LEUKOCYTES; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS;

EID: 84945440607     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/pin.12343     Document Type: Article

References (26)

1. Forouzanfar MH, Foreman KJ, Delossantos AM etal. Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis. Lancet 2011; 378: 1461-1484.
2. Stebbing J, Ellis P. An overview of drug development for metastatic breast cancer. Br J Nurs 2012; 21: S18-22.
3. Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet 2009; 373: 1463-1479.
4. Páez D, Labonte MJ, Bohanes P etal. Cancer dormancy: A model of early dissemination and late cancer recurrence. Clin Cancer Res 2012; 18: 645-653.
5. Cavallo F, Forni G. Recent advances in cancer immunotherapy with an emphasis on vaccines. Expert Rev Vaccines 2009; 8: 25-28.
6. Miller FR. Immune mechanisms in the sequential steps of metastasis. Crit Rev Oncog 1993; 4: 293-311.
7. Kaneko K, Ishigami S, Kijima Y etal. Clinical implication of HLA class I expression in breast cancer. BMC Cancer 2011; 11: 454.
8. Yu B, Zhang W. Down-regulation of CD3zeta is a breast cancer biomarker associated with immune suppression. Cell Biol Int 2011; 35: 165-169.
9. Llanes-Fernández L, Arango-Prado Mdel C etal. Association between the expression of IL-10 and T cell activation proteins loss in early breast cancer patients. Cancer Res Clin Oncol 2009; 135: 255-264.
10. Nakamura R, Sakakibara M, Nagashima T etal. Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer. Eur J Cancer 2009; 45: 2123-2131.
11. Lin A, Zhang X, Xu HH, Xu DP, Ruan YY, Yan WH. HLA-G expression is associated with metastasis and poor survival in the Balb/c nu/nu murine tumor model with ovarian cancer. Int J Cancer 2012; 131: 150-157.
12. Yan WH. Human leukocyte antigen-G in cancer: Are they clinically relevant? Cancer Lett 2011; 311: 123-130.
13. Benevolo M, Mottolese M, Tremante E etal. High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med 2011; 9: 184.
14. McIntyre JA. Immune recognition at the maternal-fetal interface: Overview. Am J Reprod Immunol 1992; 28: 127-131.
15. Le Bouteiller P, Mallet V. HLA-G and pregnancy. Rev Reprod 1997; 2: 7-13.
16. Wischhusen J, Friese MA, Mittelbronn M, Meyermann R, Weller M. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: Implications for immune escape in vivo. J Neuropathol Exp Neurol 2005; 64: 523-528.
17. King A, Allan DS, Bowen M etal. HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells. Eur J Immunol 2000; 30: 1623-1631.
18. Gooden M, Lampen M, Jordanova ES etal. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8? T lymphocytes. Proc Natl Acad Sci U S A 2011; 108: 10656-10661.
19. Zhang X, Lin A, Zhang JG etal. Alteration of HLA-F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma. Int J Cancer 2013; 132: 82-89.
20. Lin A, Zhang X, Ruan YY etal. HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer. Lung Cancer 2011; 74: 504-509.
21. Ishigami S, Arigami T, Setoyama T etal. Clinical pathological implication of human leukocyte antigen F positive gastric adenocarcinoma. J Surg Res 2013; 184: 802-806.
22. American Joint Committee on Cancer. American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 6th edn. New York: Springer, 2002.
23. de Kruijf EM, Sajet A, van Nes JG etal. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 2010; 185: 7452-7459.
24. Lee N, Ishitani A, Geraghty DE. HLA-F is a surface marker on activated lymphocytes. Eur J Immunol 2010; 40: 2308-2318.
25. Lee N, Geraghty DE. HLA-F surface expression on B cell and monocyte cell lines is partially independent from tapasin and completely independent from TAP. J Immunol 2003; 171: 5264-5271.
26. Lepin EJ, Bastin JM, Allan DS etal. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 2000; 30: 3552-3561.